Maximilian Merz, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, shared a post on LinkedIn:
“Inspired by the thought-provoking Comment from Ghulam Rehman Mohyuddin, Edward Cliff and Rajshekhar Chakraborty, Nico Gagelmann and I shared our current thoughts on the future of ciltacabtagene autoleucel in myeloma – out now in Nature Portfolio journal Nature Reviews Clinical Oncology.
Where we stand today.
Cilta-cel is one of the most powerful agents ever built to treat myeloma.
To the best of my knowledge, it remains the only agent to deliver long-lasting remissions after a SINGLE infusion without continuous treatment both, inside trials and in the real world.
- More than 10,000 patients have now been treated worldwide.
- Late toxicities only became apparent after we reached this scale – and our understanding has moved fast.
- Late neurotoxicities and movement disorders are very rare and getting rarer. They’re directly linked to tumor burden, and effective bridging has significantly reduced them.
- IEC-associated colitis is still emerging – often driven by undetected microbial pathogens. It responds to better-targeted treatments like ruxolitinib, CSA or other biologicals. And please – not week-long steroids!
- Diagnostics keep improving. Only truly refractory cases may represent rare secondary T-cell proliferations (stay tuned – an update from our group on diagnosing and treating exactly this is coming ).
And the story is only beginning
With CARTITUDE-5 and CARTITUDE-6, cilta-cel is now being tested in the frontline setting.
So the question is no longer WHETHER cilta-cel has a future in the age of bispecifics
it’s HOW we sequence the two.
The future of cilta-cel has just begun.”
Title: The future of ciltacabtagene autoleucel in multiple myeloma has just begun
Authors: Maximilian Merz, Nico Gagelmann
Read the Full Article.
Other articles featuring Maximilian Merz on OncoDaily.